Company Overview and News

1
TPRE / Third Point Reinsurance Ltd. 8-K (Current Report)

2018-09-07 sec.gov - 1
Document UNITED STATES
TPRE

90
Tracking Dan Loeb's Third Point Portfolio - Q2 2018 Update

2018-08-12 seekingalpha - 7
Dan Loeb's 13F portfolio value increased from $13.32B to $14.35B this quarter. The number of positions decreased from 40 to 38.
ATHTF STZ.B TWX CRM DOW DOV MELI PBF TPRE WP KDMN STZ UTX BKI TWC PVH DVMT FPAC.U GOOGL MSFT APY MHK TPNTF GRBK FB DOV.WI LEN NXPI PYPL NFLX BAX GOOG LEN.B MPC PAGS ADBE SPGI EGN MON ICE SHY CWH EA WYNN ANTM DWDP BID BLK V DHR ANTX

 
Third Point Reinsurance's (TPRE) CEO Rob Bredahl on Q2 2018 Results - Earnings Call Transcript

2018-08-01 seekingalpha
Third Point Reinsurance Ltd. (NYSE:TPRE) Q2 2018 Earnings Conference Call August 1, 2018 8:30 AM ET
TPRE MS

2
Third Point exits Facebook after 'very disappointing quarter'

2018-08-01 reuters
(Reuters) - Third Point LLC has sold its 4-million-share stake in Facebook Inc (FB.O), the hedge fund’s billionaire founder said on Wednesday, following disappointing results from the social networking giant.
FB TPRE

 
TPRE / Third Point Reinsurance Ltd. 10-Q (Quarterly Report)

2018-07-31 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON
TPRE

 
TPRE / Third Point Reinsurance Ltd. 8-K (Current Report)

2018-07-31 sec.gov
Document UNITED STATES
TPRE

6
Ackman’s Comeback: How to Ride His Revival - Barron's

2018-07-17 barrons - 2
This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.
GLRE TPRE ADP TPOG VRX PSHZF BAX UTX QSR.WI CMG ADPVV TPOU QSR

 
TPRE or AXS: Which Is the Better Value Stock Right Now?

2018-07-10 zacks
Investors interested in stocks from the Insurance - Property and Casualty sector have probably already heard of Third Point Reinsurance (TPRE - Free Report) and Axis Capital (AXS - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
TPRE

1001
Tracking Dan Loeb's Third Point Portfolio - Q1 2018 Update

2018-05-22 seekingalpha - 10
Dan Loeb's 13F portfolio value decreased from $13.86B to $13.32B this quarter. The number of positions decreased from 44 to 40.
PCG ATHTF STZ.B TWX CVS CRM SHW GGAL HON AABA AVGO DOW DOV MELI MAC AET MMM PBF GD TPRE WP KDMN UTX STZ BKI TWC BABA DVMT GOOGL MSFT APY MHK QCOM GRBK MGM FB DOV.WI LEN NXPI PAM PE NFLX PF GOOG BAX LEN.B MPC PAGS ADBE SPGI RSPP VMC MON ICE SWN HON EA WYNN LYB FTI.WI FMC ANTM DWDP BID NEXA BLK XRAY T SUPV DHR ANTX

13
Third Point Reinsurance's (TPRE) CEO Rob Bredahl on Q1 2018 Results - Earnings Call Transcript

2018-05-13 seekingalpha - 1
Greetings, and welcome to the Third Point Reinsurance First Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
TPRE MS

1
Third Point's Dan Loeb to increase bets against the stock market

2018-05-13 cnbc - 1
Following a quarter in which his two flagship funds posted losses, the head of Third Point said he is increasing short positions that proved to be profitable during an otherwise rough first quarter.
TPRE

 
TPRE / Third Point Reinsurance Ltd. 8-K (Current Report)

2018-05-11 sec.gov
Document UNITED STATES
TPRE

 
TPRE / Third Point Reinsurance Ltd. 10-Q (Quarterly Report)

2018-05-10 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON
TPRE

 
Loeb's Third Point Boosts Short Wagers on Market Disruption - Bloomberg

2018-05-10 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
TPRE

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: G8827U100